Compile Data Set for Download or QSAR
Report error Found 318 Enz. Inhib. hit(s) with all data for entry = 1937
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256521(US9481648, 20 | US9790174, Example 20 | US10435361...)
Affinity DataIC50: 6nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256511(US9481648, 9 | US9790174, Example 9 | US10435361, ...)
Affinity DataIC50: 8nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347466(3-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-(methylsu...)
Affinity DataIC50: 9nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256515(US9481648, 13 | US9790174, Example 13 | US10435361...)
Affinity DataIC50: 9nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256519(US9481648, 18 | US9790174, Example 18 | US10435361...)
Affinity DataIC50: 10nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347465(3-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-(methylsu...)
Affinity DataIC50: 11nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256516(US9481648, 14 | US9790174, Example 14 | US10435361...)
Affinity DataIC50: 11nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256524(US9481648, 23 | US9790174, Example 23 | US10435361...)
Affinity DataIC50: 11nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256524(US9481648, 23 | US9790174, Example 23 | US10435361...)
Affinity DataIC50: 11nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256534(US9481648, 33 | US9790174, Example 33 | US10435361...)
Affinity DataIC50: 11nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256503(US9481648, 1 | US9790174, Example 1)
Affinity DataIC50: 12nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256538(US9481648, 37 | US9790174, Example 37 | US10435361...)
Affinity DataIC50: 12nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256536(US9481648, 35 | US9790174, Example 35 | US10435361...)
Affinity DataIC50: 13nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256570(US9481648, 69 | US9790174, Example 69 | US10435361...)
Affinity DataIC50: 13nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347463(N-(5-(tert-Butyl)-2-methoxy-3-(3-(4-((2-((3-methox...)
Affinity DataIC50: 14nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256525(US9481648, 24 | US9790174, Example 24 | US10435361...)
Affinity DataIC50: 14nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256547(US9481648, 46 | US9790174, Example 46 | US10435361...)
Affinity DataIC50: 15nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256548(US9481648, 47 | US9790174, Example 47 | US10435361...)
Affinity DataIC50: 15nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256552(US9481648, 51 | US9790174, Example 51 | US10435361...)
Affinity DataIC50: 15nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256537(US9481648, 36 | US9790174, Example 36 | US10435361...)
Affinity DataIC50: 16nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347469(N-(5-(tert-Butyl)-3-(3-(2,3-dichloro-4-((2-((3-met...)
Affinity DataIC50: 18nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256581(US9481648, 80 | US9790174, Example 80 | US10435361...)
Affinity DataIC50: 18nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256530(US9481648, 29 | US9790174, Example 29 | US10435361...)
Affinity DataIC50: 19nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256535(US9481648, 34 | US9790174, Example 34 | US10435361...)
Affinity DataIC50: 19nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347462(3-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-(methylsu...)
Affinity DataIC50: 20nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM256547(US9481648, 46 | US9790174, Example 46 | US10435361...)
Affinity DataIC50: 20nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347470(N-(5-(tert-Butyl)-2-methoxy-3-(3-(4-((2-((3-methox...)
Affinity DataIC50: 21nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256598(US9481648, 84(h) | US9790174, Example 84(h) | US10...)
Affinity DataIC50: 21nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256556(US9481648, 55 | US9790174, Example 55 | US10435361...)
Affinity DataIC50: 22nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256584(US9481648, 83(a) | US9790174, Example 83(a) | US10...)
Affinity DataIC50: 22nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256567(US9481648, 66 | US9790174, Example 66 | US10435361...)
Affinity DataIC50: 23nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256578(US9481648, 77 | US9790174, Example 77 | US10435361...)
Affinity DataIC50: 23nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM142019(US8927563, I | US9481648, 16 | US9790174, Example ...)
Affinity DataIC50: 24nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256535(US9481648, 34 | US9790174, Example 34 | US10435361...)
Affinity DataIC50: 25nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347486(3-((4-((4-(3-(5-(tert-Butyl)-2-methoxy-3-(methylsu...)
Affinity DataIC50: 26nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256530(US9481648, 29 | US9790174, Example 29 | US10435361...)
Affinity DataIC50: 26nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM256511(US9481648, 9 | US9790174, Example 9 | US10435361, ...)
Affinity DataIC50: 27nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256515(US9481648, 13 | US9790174, Example 13 | US10435361...)
Affinity DataIC50: 28nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256517(US9481648, 15 | US9790174, Example 15 | US10435361...)
Affinity DataIC50: 28nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256517(US9481648, 15 | US9790174, Example 15 | US10435361...)
Affinity DataIC50: 28nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM256534(US9481648, 33 | US9790174, Example 33 | US10435361...)
Affinity DataIC50: 28nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256560(US9481648, 59 | US9790174, Example 59 | US10435361...)
Affinity DataIC50: 28nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256597(US9481648, 84(g) | US9790174, Example 84(g) | US10...)
Affinity DataIC50: 28nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM256521(US9481648, 20 | US9790174, Example 20 | US10435361...)
Affinity DataIC50: 29nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256540(US9481648, 39 | US9790174, Example 39 | US10435361...)
Affinity DataIC50: 29nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256599(US9481648, 85(a) | US9790174, Example 85(a) | US10...)
Affinity DataIC50: 29nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256525(US9481648, 24 | US9790174, Example 24 | US10435361...)
Affinity DataIC50: 30nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256577(US9481648, 76 | US9790174, Example 76 | US10435361...)
Affinity DataIC50: 31nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256563(US9481648, 62 | US9790174, Example 62 | US10435361...)
Affinity DataIC50: 32nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256521(US9481648, 20 | US9790174, Example 20 | US10435361...)
Affinity DataIC50: 33nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 318 total ) | Next | Last >>
Jump to: